Understanding and evaluating clinical trials [1] (multiple letters)

Journal of the American Academy of Dermatology

Volumn 37, Issue 5 I, 1997, Pages 803-804

  Rahlfs, V W ^a   Bigby, M ^a   Gadenne, A S ^a  

^a idv Data Analysis and Study Planning   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; DRUG RESEARCH; FOLLOW UP; LETTER; METHODOLOGY; PRIORITY JOURNAL; SAMPLE; STATISTICAL ANALYSIS;

EID: 0030726750     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0190-9622(97)70126-9     Document Type: Letter

References (8)

1. European Union Good biostatistical practice, note for guidance. Biostatistical methodology in clinical trials in applications for marketing authorizations for medicinal products December 1994 : CPMP Efficacy Working Party Brussels, Belgium
2. GA Diamond JS Forrester Clinical trials and statistical verdicts: probable grounds for appeal Ann Intern Med 98 1983 385 394
3. WS Browner TB Newman Are all significant P values created equal? The analogy between diagnostic tests and clinical research JAMA 257 1987 2459 2463
4. DG Altman Statistics and ethics in medical research Statistics in practice 1982 : British Medical Association London Chapter VI
5. TA Louis PW Lavori JC Bailar III M Polansky Crossover and self-controlled designs in clinical research Engl J Med 310 1984 24 31
6. H Zimmermann VW Rahlfs Model building and testing for the change-over design Biomed J 22 1980 197 210
7. M Hills P Armitage The two-period cross-over clinical trial Br J Clin Pharmacol 8 1979 7 20
8. TESTIMATE PC program for calculation of confidence intervals 1994 : idv Gauting Munich